Other formats:
BibTeX
LaTeX
RIS
@article{964785,
author = {Gumulec, Jaromír and Sochor, Jiří and Hlavna, Marián and Sztalmachová, Markéta and Křížková, Soňa and Babula, Petr and Hrabec, Roman and Rovný, Arne and Adam, Vojtěch and Eckschlager, Tomáš and Kizek, René and Masařík, Michal},
article_number = {3},
doi = {http://dx.doi.org/10.3892/or.2011.1587},
keywords = {prostate cancer; tumour marker; prognostic marker; immunodetection; electrochemistry; polymerase chain reaction; molecular biology techniques},
language = {eng},
issn = {1021-335X},
journal = {Oncology Reports},
title = {Caveolin-1 as a potential high-risk prostate cancer biomarker},
volume = {27},
year = {2012}
}
TY - JOUR
ID - 964785
AU - Gumulec, Jaromír - Sochor, Jiří - Hlavna, Marián - Sztalmachová, Markéta - Křížková, Soňa - Babula, Petr - Hrabec, Roman - Rovný, Arne - Adam, Vojtěch - Eckschlager, Tomáš - Kizek, René - Masařík, Michal
PY - 2012
TI - Caveolin-1 as a potential high-risk prostate cancer biomarker
JF - Oncology Reports
VL - 27
IS - 3
SP - 831-841
EP - 831-841
SN - 1021335X
KW - prostate cancer
KW - tumour marker
KW - prognostic marker
KW - immunodetection
KW - electrochemistry
KW - polymerase chain reaction
KW - molecular biology techniques
N2 - Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.
ER -
GUMULEC, Jaromír, Jiří SOCHOR, Marián HLAVNA, Markéta SZTALMACHOVÁ, Soňa KŘÍŽKOVÁ, Petr BABULA, Roman HRABEC, Arne ROVNÝ, Vojtěch ADAM, Tomáš ECKSCHLAGER, René KIZEK and Michal MASAŘÍK. Caveolin-1 as a potential high-risk prostate cancer biomarker. \textit{Oncology Reports}. 2012, vol.~27, No~3, p.~831-841. ISSN~1021-335X. Available from: https://dx.doi.org/10.3892/or.2011.1587.
|
